THALES
Thales will provide its SelTrac™ Communications Based Train Control (CBTC) signalling solution in South Korea, Turkey and China, after signing three urban rail signalling contracts. Despite the current Covid-19 pandemic, governments around the globe are committed to progressing forward with crucial public transportation developments and Thales’s technology will be an important part of these projects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200611005010/en/
Incheon Metro, Line 2 Capacity Increase
Incheon Subway Line 2 is part of the overall Seoul Metropolitan Subway network, which is currently undergoing modernisation to improve the performance and reliability of the network.
Thales has signed a contract with DaeaTi, a leading Korean railway signalling technology player, to provide new signalling equipment for the Incheon Line 2 depot capacity increase, which will address the need to park the six new driverless trains safely. The trains will be delivered in 2021 with Thales’ Vehicle On Board Controller (VOBC) which were separately contracted with train contractor Woojin Ind in 2019. Since the start of revenue service of Incheon’s L2 metro in July 2016, passenger flow has doubled from 90,000 to 180,000 a day, prompting the need for six additional trains to cope with the increase.
Thales has been working with Incheon City and Incheon Transit Corporation since 2009 on the Incheon Line 2, focusing on better serving the public transit users of Incheon as their common goal.
Istanbul Metro, Line M10
The M10 Line will be the first metro line to the Sabiha Gokcen International Airport, the second busiest airport in Turkey, on the Asian side of Istanbul and will comprise 7.5km of track and four stations. Gülermak-YSE Joint Venture is the main project contractor, and Thales has been contracted by Çelikler Taahhut, a major construction company, to install their SelTrac™ CBTC system on the new M10 Line in Istanbul Turkey, connecting the Kaynarca district and the Sabiha Gokcen Airport. The M4 line is already equipped with Thales’s SelTrac™ solution and the new contract will extend the existing technology onto the new line.
Upon completion, the new line will allow connectivity between the Airport and major cities, taking 13 minutes from the airport to Kaynarca, 46 minutes to Kadikoy and an hour to Yenikapı, on the European side. This project is part of the Government of Turkey’s key priorities to improve transportation in major cities , with a strong focus on connectivity between transportation hubs.
Nanchang Metro, Line 4
Thales SEC Transportation System Company Limited (TST), Thales’ Joint Venture with Shanghai Electric, will provide the signalling for the first phase of the new metro Line 4 in Nangchang, the capital and largest city of the Jiangxi Province in eastern China. The first phase of the Nanchang Metro Line 4 will expand from Baimashan Station to Yuweizhou Station, passing through the main area of Nanchang to connect five districts. The first phase of the Nanchang Metro Line 4 has a total operational length of 39.6km, with 34.1km underground, 5.5km elevated and 29 stations, making it the longest metro line in Nanchang, with the largest number of stations. .
TST is familiar with the network as they have previously delivered signalling systems to the Line 1 and Line 2 of the Nangchang Metro. This project will allow the Nanchang Metro to continue to support the rapidly growing population of Nanchang.
In parallel in China, on April 23rd, Hangzhou Metro Line 16, connecting Hangzhou downtown with Lin’an District, entered into revenue service smoothly. This very fast metro line relies on Thales SEC Transport signalling system technologies for maximum safety and efficiency, ensuring everyday pleasant and reliable journeys for local passengers and showing Thales commitment to China ground transportation.
“During the Covid-19 period, we are continuing to work together with our global partners in major cities such as Incheon, Istanbul, and Nanchang. Thales is committed to providing state-of-the-art SelTrac™ CBTC signalling technology. No matter the network or city, we continue to tailor our solution to meet the needs of the customer and provide reliable transportation solutions for their passengers.” – Dominique Gaiardo, Vice President and Managing Director for Thales’ urban rail signalling business.
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.
PLEASE VISIT
Thales Group
Transportation
View source version on businesswire.com: https://www.businesswire.com/news/home/20200611005010/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom